Background\ud Agitation is a common and distressing symptom in patients with Alzheimer’s disease.\ud Cholinesterase inhibitors improve cognitive outcomes in such patients, but the\ud benefits of these drugs for behavioral disturbances are unclear.\ud Methods\ud We randomly assigned 272 patients with Alzheimer’s disease who had clinically significant\ud agitation and no response to a brief psychosocial treatment program to receive\ud 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks.\ud The primary outcome was a change in the score on the Cohen–Mansfield Agitation\ud Inventory (CMAI) (on a scale of 29 to 203, with higher scores indicating more agitation)\ud at 12 weeks.\ud Results\ud There was no significant difference between the effects of donepezil and those of placebo\ud on the basis of the change in CMAI scores from baseline to 12 weeks (estimated\ud mean difference in change [the value for donepezil minus that for placebo], −0.06;\ud 95% confidence interval [CI], −4.35 to 4.22). Twenty-two of 108 patients (20.4%) in the\ud placebo group and 22 of 113 (19.5%) in the donepezil group had a reduction of 30%\ud or greater in the CMAI score (the value for donepezil minus that for placebo, −0.9 percentage\ud point; 95% CI, −11.4 to 9.6). There were also no significant differences between\ud the placebo and donepezil groups in scores for the Neuropsychiatric Inventory,\ud the Neuropsychiatric Inventory Caregiver Distress Scale, or the Clinician’s Global\ud Impression of Change.\ud Conclusions\ud In this 12-week trial, donepezil was not more effective than placebo in treating agitation\ud in patients with Alzheimer’s disease. (ClinicalTrials.gov number, NCT00142324.
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.